- BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q2 GAAP EPS of -$0.32 beats by $0.03 .
- Revenue of $65.53M (+31.1% Y/Y) beats by $1.7M .
- FY 2022 ORLADEYO net revenue expected to be between $255 million and $265 million
- Based on the reduced spending on the BCX9930 program in the first half of the year, and lower than projected spending on the program for the remainder of the year, the company now expects operating expenses for full year 2022, not including non-cash stock compensation, to be between $390 million and $400 million.
For further details see:
BioCryst Pharmaceuticals GAAP EPS of -$0.32 beats by $0.03, revenue of $65.53M beats by $1.7M